1. Home
  2. CADL vs SNN Comparison

CADL vs SNN Comparison

Compare CADL & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Candel Therapeutics Inc.

CADL

Candel Therapeutics Inc.

HOLD

Current Price

$10.84

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Smith & Nephew SNATS Inc.

SNN

Smith & Nephew SNATS Inc.

HOLD

Current Price

$27.60

Market Cap

12.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CADL
SNN
Founded
1999
1856
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
12.3B
IPO Year
2021
2002

Fundamental Metrics

Financial Performance
Metric
CADL
SNN
Price
$10.84
$27.60
Analyst Decision
Strong Buy
Hold
Analyst Count
7
2
Target Price
$19.00
$36.25
AVG Volume (30 Days)
1.1M
1.7M
Earning Date
05-14-2026
03-16-2026
Dividend Yield
N/A
2.48%
EPS Growth
58.62
N/A
EPS
N/A
N/A
Revenue
$125,000.00
N/A
Revenue This Year
N/A
$8.58
Revenue Next Year
N/A
$5.60
P/E Ratio
N/A
$64.97
Revenue Growth
N/A
N/A
52 Week Low
$4.35
$27.23
52 Week High
$14.00
$37.51

Technical Indicators

Market Signals
Indicator
CADL
SNN
Relative Strength Index (RSI) 41.77 36.68
Support Level $9.40 $27.23
Resistance Level $11.36 $31.36
Average True Range (ATR) 0.69 0.53
MACD -0.28 -0.02
Stochastic Oscillator 27.99 15.65

Price Performance

Historical Comparison
CADL
SNN

About CADL Candel Therapeutics Inc.

Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

About SNN Smith & Nephew SNATS Inc.

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 40% of the UK-based firm's revenue comes from orthopedic products, and another 31% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the US, just over 30% is from other developed markets, and emerging markets account for the remainder.

Share on Social Networks: